Saturday 17 October 2026
Export CLOV’s income statement to Excel — free account
Clover Health Investments, Corp.
CLOV Healthcare Healthcare Plans
Clover Health Investments, Corp.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, up 40.3% from fiscal 2024. In the quarter to June 2026, revenue grew 55.6%, EPS grew 350.0% and free cash flow grew 406.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
4.48
0.20
−4.27%
Follow CLOV
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 6 | 6 | 4 | 4 | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
P/S ratio |
0.63 | 1.13 | 0.37 | 0.41 | 1.04 | 2.21 | 0.00 | — |
Altman Z-Score |
0.44 | 0.92 | (2.96) | (2.31) | (0.32) | (2.89) | — | — |
P/FCF ratio |
0.00 | 46.37 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
(12.26) | (9.94) | (11.78) | (7.83) | (6.05) | (14.99) | — | — |
P/Operating CF |
(17.65) | (17.98) | (1.79) | (2.16) | (19.16) | (24.83) | (24.24) | — |
Beneish M-Score |
(1.72) | (3.07) | (3.42) | (3.03) | — | — | — | — |
P/B ratio |
3.90 | 4.52 | 1.62 | 1.27 | 2.85 | 0.00 | 121,753.54 | — |
Price to Tangible BV |
3.94 | 4.56 | 1.63 | 1.34 | 2.87 | 0.00 | 121,753.54 | — |
EV/Sales |
0.57 | 0.98 | 0.20 | 0.13 | 0.65 | 2.26 | 0.00 | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
EV/Operating CF |
(16.50) | 38.56 | (1.72) | (0.68) | (3.41) | (12.81) | 0.00 | — |
EV/FCF |
(16.01) | 40.36 | (1.71) | (0.67) | (3.40) | (12.73) | 0.00 | — |
Quick Ratio |
1.03 | 1.28 | 1.15 | 0.99 | 1.82 | 0.89 | 0.00 | — |
Current Ratio |
1.47 | 1.61 | 1.64 | 1.45 | 2.02 | 1.16 | 0.00 | — |
Net Debt/EBITDA |
1.40 | 4.72 | 1.14 | 1.16 | 0.96 | (0.43) | 0.00 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.19% | 2.10% | 47.60% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.04 | (0.21) | 0.00 | — |
Asset Turnover |
3.43 | 2.38 | 1.83 | 1.25 | 2.42 | 5.03 | 9,217.67 | — |
Operating CF/Net income |
0.78 | (0.81) | 0.68 | 0.60 | 0.48 | 0.87 | 0.44 | — |
Capex/Depreciation |
13.01 | 1.30 | 0.39 | 15.62 | (0.05) | (0.03) | 0.00 | — |
Interest Coverage |
— | — | (29,332.73) | (215.05) | (199.50) | (2.58) | (7.91) | — |
| (26.33%) | (13.71%) | (66.34%) | (75.78%) | 1,591.19% | 44.48% | 117.88% | — | |
| (15.25%) | (7.47%) | (30.94%) | (38.60%) | (96.51%) | (102.03%) | (725,298.11%) | — | |
ROIC |
(28.37%) | (23.91%) | (255.82%) | (756.23%) | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(81.15%) | (31.88%) | (124.09%) | (170.43%) | (153.78%) | (493.60%) | 308,251.69% | — |
Average Days of Receivables |
17.99 | 13.72 | 18.58 | 31.36 | 15.45 | 27.18 | 0.00 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
22.85% | 29.82% | 34.93% | 43.99% | 30.28% | 28.55% | 40.52% | — |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.02 | 0.00 | 0.02 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
5.39% | 8.34% | 11.18% | 14.98% | 11.12% | 1.05% | 0.71% | — |
Graham Net Nets |
0.06 | 0.07 | 0.31 | 0.38 | 0.22 | (0.46) | 0.00 | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.47 | 0.00 | — |
Earnings Yield |
(7.34%) | (2.86%) | (46.88%) | (75.79%) | (38.44%) | (9.17%) | 0.00% | — |
Free Cash Flow Yield |
(5.73%) | 2.16% | (31.38%) | (46.06%) | (18.43%) | (8.01%) | 0.00% | — |
Revenue per Share |
3.76 | 2.80 | 2.61 | 2.30 | 3.56 | 7.59 | 5.26 | — |
Operating CF per Share |
(0.13) | 0.07 | (0.30) | (0.43) | (0.68) | (1.34) | (1.82) | — |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | 0.00 | (0.01) | 0.00 | — |
Free Cash Flow per Share |
(0.13) | 0.07 | (0.30) | (0.44) | (0.69) | (1.34) | (1.82) | — |
Cash per Share |
0.23 | 0.45 | 0.49 | 0.70 | 1.49 | 1.09 | 0.00 | — |
Shareholders Equity per Share |
0.60 | 0.70 | 0.59 | 0.75 | 1.31 | (6.91) | 0.00 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
0.60 | 0.70 | 0.59 | 0.75 | 1.31 | (6.91) | 0.00 | — |
Free Cash Flow |
(68.98) | 33.29 | (145.25) | (208.39) | (283.05) | (119.19) | (159.90) | — |
Working Capital |
99.03 | 129.61 | 166.86 | 193.49 | 379.92 | 25.55 | (0.12) | — |
Capital Expenditures |
(2.04) | (1.56) | (0.58) | (4.47) | (0.72) | (0.69) | (0.02) | — |
Net Current Asset Value |
75.55 | 103.53 | 143.69 | 173.26 | 341.06 | (690.66) | (0.12) | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | ||||||||
Depreciation/Fixed assets |
(0.02) | (0.22) | (0.30) | (0.05) | 6.63 | 10.34 | 0.00 | — |
Cash ROIC |
(16.08%) | 5.92% | (27.79%) | (30.06%) | (24.10%) | 30.62% | 908,511.36% | — |
Accounts Receivable Turnover |
26.29 | 23.70 | 15.92 | 14.01 | 26.18 | 11.97 | 0.00 | — |
Accounts Payable Turnover |
44.32 | 28.05 | 28.86 | 32.79 | 52.76 | 20.07 | 0.00 | — |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
8.43 | 12.54 | 13.51 | 11.93 | 6.62 | 18.97 | 0.00 | — |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Receivables |
73.20 | 57.85 | 79.18 | 78.26 | 56.22 | 56.22 | — | — |
Average Payables |
35.39 | 35.87 | 34.81 | 30.29 | 29.40 | 29.40 | — | — |
Average Assets |
560.88 | 575.71 | 689.65 | 879.71 | 609.03 | 133.68 | 0.05 | — |
Average Common Equity |
324.92 | 313.77 | 321.64 | 448.10 | (36.94) | (306.61) | (308.56) | — |
Columns are period end dates